American geneticist claims Bigfoot is real after sequencing his genomes in a DNA study

American geneticist claims Bigfoot is real after sequencing his genomes in a DNA study
Last November team of American scientists led Dr Melba Ketchum of DNA diagnostics in Nacogdoches, Texas, announced that they have found proof that the legendary ‘Sasquatch’ or ‘Bigfoot’ actually exists. After sequencing three Bigfoot genomes the team concluded that Sasquatch is extant in North America and is a human relative that arose approximately 13 thousand years ago as a hybrid cross of modern Homo Sapiens with some unknown primate species. The Voice of Russia contacted Dr Ketchum to ask her for the details of one of the most controversial projects of the decade.
Voice of Russia: Before we get into details, I would like to ask you how you came up with the idea to study bigfoot. At the very least, this is a very unusual choice of study for a serious geneticist. Dr Melba Ketchum: Well, I must say that it came to me, I did not choose it. What we do in our laboratory is we perform species identification mostly for forensic use. However, over the years we have also been receiving samples that supposedly contained DNA of a Bigfoot or a Sasquatch. Five years ago one of the TV show production companies asked us to identify some samples one of which was allegedly a yeti sample. At the same time I also received the samples from North America Bigfoot Search Organization. We did not have enough DNA to go far with neither of the samples but we still got marginally interesting results. When the TV show aired we got a huge amount of calls from people who wanted to submit DNA samples to us, and, out of curiosity, we agreed. When we started testing them we realized that something might come out from this research. To tell you the truth, I did not believe in the existence of Sasquatch before we began our tests. Voice of Russia: In your previous interviews you said that when you submitted your project for peer-review you encountered the worst scientific bias which you called the ‘Galileo Effect’. Some journals would not even read your manuscript when you sent them a pre-submission enquiry. In your opinion, why were you rejected by the mainstream scientific journals? Is it because the modern science is not yet ready for such ground-breaking research? Dr Melba Ketchum: Yes, the modern science is not yet ready for it. There is so much hype surrounding it that the scientific community feels that the research cannot be credible. For most of the scientific world, the results of our study cannot be valid because they know that yeti does not exist and thus the project is merely a hoax, an ad campaign. As a result, the scientists did not even want to look through it. Their unwillingness to even consider the possibility that a mythical creature might actually be real might leads them to invent the reasons why our research was invalid. Another reason why most of the scientific world turned their backs on our research is that the existence of hybrid DNA is a very unpopular theory, even though it is a proven scientific fact that most Caucasian individuals have at least two to three percent Neanderthal genes as well as a lot of South-East Asian people have up to five percent of Denisova genes. Those reviewers who finally agreed to read the paper then came back to me asking for the information that was already in the manuscript, so I knew they did not even read it. Moreover, when the reviewers failed to find any errors in our research they simply asserted that it was ‘contaminated’. Given that most of our project team consisted of forensic scientists we are sure that there is no contamination in our research. In this sense, it seems to me that contamination is the only excuse that the reviewers can come up with to prevent the publication of our study. More generally, one might recall that nearly all major breakthroughs in science have been met with great skepticism or immediately rejected as invalid. This why I call the situation in which we know find ourselves a ‘Galilio Effect’. Every-so-often innovative research projects are not accepted by the scientific community up until the scientist passes away. Voice of Russia: Oh, I am sure this will not be the case with your research! So, your 5-year long DNA study confirms the existence of a novel hominin hybrid species that reside in North America. Is there a possibility that these hybrids can be found somewhere else? In Russia, for example? Dr Melba Ketchum: We actually have some Russian samples which we are currently studying. We are just at the beginning of the sequencing process but we believe that these DNA samples will have the same makeup as North American ones. In this sense, we think that Russian hybrids and North American Sasquatch are all related individuals. More generally, we believe that Bigfoot species can be found all over the world. Only in the United States there are over 30 thousand documented sightings of Sasquatch and probably three times more undocumented eyewitness testimonies. According to my Russian colleague Dr Igor Burtsev there are also numerous documented yeti sightings in Siberia. Voice of Russia: Tell us a bit more about your methods of research. I heard that you used mitochondrial DNA that you obtained from leftover blueberry bagels eaten by a family of 10 bigfoot’s who live in Michigan. Dr Melba Ketchum: Oh, this is not true! Admittedly, one can obtain a DNA sample from anything that an individual ate or chewed because saliva is a very good source of DNA, but we did not use any bagels. We made plastic containers where we placed a piece of food, such as chocolate. This way, we could ensure that only a creature that had ‘hands’ could gain access to the food. We then used food remnants as our DNA samples. This is one of the very few methods that we can use to study Sasquatch. It is almost impossible, for example to get any photographic record or a body. Although, I must say that there is now a photographic record that will soon be released. Voice of Russia: In your statement published last November you suggested that the government at all levels must recognize Sasquatch as an indigenous people and immediately protect their human and Constitutional rights against those who would see in their physical and cultural differences a ‘license’ to hunt, trap, or kill them. Can you elaborate on this? Dr Melba Ketchum: Basically, Bigfoot are a particular type of people, so we do not want them hunted, harassed, or being chased through the woods. The wood is their home. They have a right to privacy. People should leave them alone. We are not asking the government to give them large areas of land or anything like that. Sasquatch do not need them – they live right under our noses and we do not see them. Also, people should be aware that an encounter with a Sasquatch might not be as pleasant as they think. People should not be afraid of them but, at the same time, they should realize that if harassed, a Sasquatch can fight back. So, you might need to think twice before you argue with someone who is twice your size. Voice of Russia: Taking into consideration all the obstacles that stand on your way in publishing your research, do you intend to continue your project? Dr Melba Ketchum: First of all, the DNA sequencing is a very complicated technique and it might take years to go through it in full. So, yes, we do continue our research. Second of all, we intend to do a cultural assessment of Sasquatch. We aim to learn how Sasquatch behave and whether they have any specific rituals. Source: Voice of Russia
Read More........

Bionic eye good to go:artificial retina receives FDA approval

The U.S. Food and Drug Administration (FDA) granted market approval to an artificial retina technology today, the first bionic eye to be approved for patients in the United States. The prosthetic technology was developed in part with support from the National Science Foundation (NSF). The device, called the Argus® II Retinal Prosthesis System, transmits images from a small, eye-glass-mounted camera wirelessly to a microelectrode array implanted on a patient's damaged retina. The array sends electrical signals via the optic nerve, and the brain interprets a visual image. While the Argus II is a major breakthrough in retinal  prosthetics, researchers are continuing their research. This third-generation retina chip, itself still very early in the development stage, contains 1,000 electrodes and was developed by Wentai Liu, a professor of bioengineering at the UCLA Henry Samueli School of Engineering and Applied Science and his colleagues. Early engineering done by Liu and his team was licensed to Second Sight
for the Argus II Retinal Prosthesis  System. The FDA approval currently applies to individuals who have lost sight as a result of severe to profoundretinitis pigmentosa (RP), an ailment that affects one in every 4,000 Americans. The implant allows some individuals with RP, who are completely blind, to locate objects, detect movement, improve orientation and mobility skills and discern shapes such as large letters.The Argus II is manufactured by, and will be distributed by, Second Sight Medical Products of Sylmar, Calif., which is part of the team of scientists and engineers from the university, federal and private
Credit: Wentai Liu, UCLA
sectors who spent nearly two decades developing the  system with public and private investment. "Seeing my grandmother go blind motivated me to pursue ophthalmology and biomedical engineering to develop a treatment for patients for whom there was no foreseeable cure," says the technology's co-developer, Mark Humayun, associate director of research at the Doheny Eye Institute at the University of Southern California and director of the NSF Engineering Research Center for Biomimetic MicroElectronic Systems(BMES). "It was an interdisciplinary approach grounded in biomedical engineering that has allowed us to develop the Argus II, making it the first commercially approved retinal implant in the world to
 restore sight to some blind patients," Humayun adds. The effort by Humayun and his colleagues has received early and continuing support from NSF, the National Institutes of Health and the Department of Energy, with grants totaling more than $100 million. The private sector's support nearly matched that of the federal government. "The retinal implant exemplifies how NSF grants for high-risk, fundamental research can directly result in ground-breaking technologies decades later," said Acting NSF Assistant Director for Engineering Kesh Narayanan. "In collaboration with the Second Sight team and the courageous patients who volunteered to have experimental surgery to implant the first-generation devices, the researchers of NSF's Biomimetic MicroElectronic Systems Engineering Research Center are developing technologies that may ultimately have as profound an impact on blindness as the cochlear implant has had for hearing loss." Although some treatments to slow the progression of degenerative diseases of the retina are available, no treatment has existed that could replace the function of lost photoreceptors in the eye. The researchers began their retinal prosthesis research in the late 1980s to address that need, and in 1994 Humayun received his first NSF grant, an NSF Young Investigator Award, which built upon additional support from the Whittaker Foundation. Humayun used the funding to develop the first conceptualization of the Argus II's underlying artificial retina technology. Since that time, he and his collaborators--including Wentai Liu of the University of California, Los Angeles and fellow USC researchers Jim Weiland and Eugene de Juan, Jr.--received six additional NSF grants, totaling $40 million, some of which was part of NSF's funding for BMES, launched in 2003. BMES drives research into a range of sophisticated prosthetic technologies to treat blindness, paralysis and other conditions. "We were encouraged by the team's exploratory work in the 1980s and 1990s, supported by NSF and others, which revealed that healthy neural pathways can carry information to the brain, even though other parts of the eye are damaged," adds Narayanan. "The retinal prosthesis they developed from that work simulates the most complex part of the eye. Based on the promise of that implant, we decided in 2003 to entrust the research team with an NSF Engineering Research Center," says Narayanan. "The center was to scale up technology development and increase device sensitivity and biocompatibility, while simultaneously preparing students for the workforce and building partnerships to speed the technology to the marketplace, where it could make a difference in people's lives. The center has succeeded with all of those goals." The researchers' efforts have bridged cellular biology--necessary for understanding how to stimulate the retinal ganglion cells without permanent damage--with microelectronics, which led to the miniaturized, low-power integrated chip for performing signal conversion, conditioning and stimulation functions. The hardware was paired with software processing and tuning algorithms that convert visual imagery to stimulation signals, and the entire system had to be incorporated within hermetically sealed packaging that allowed the electronics to operate in the vitreous fluid of the eye indefinitely. Finally, the research team had to develop new surgical techniques in order to integrate the device with the body, ensuring accurate placement of the stimulation electrodes on the retina. "The artificial retina is a great engineering challenge under the interdisciplinary constraint of biology, enabling technology, regulatory compliance, as well as sophisticated design science," adds Liu. "The artificial retina provides an interface between biotic and abiotic systems. Its unique design characteristics rely on system-level optimization, rather than the more common practice of component optimization, to achieve miniaturization and integration. Using the most advanced semiconductor technology, the engine for the artificial retina is a 'system on a chip' of mixed voltages and mixed analog-digital design, which provides self-contained power and data management and other functionality. This design for the artificial retina facilitates both surgical procedures and regulatory compliance." The Argus II design consists of an external video camera system matched to the implanted retinal stimulator, which contains a microelectrode array that spans 20 degrees of visual field. The NSF BMES ERC has developed a prototype system with an array of more than 15 times as many electrodes and an ultra-miniature video camera that can be implanted in the eye. However, this prototype is many years away from being available for patient use. "The external camera system-built into a pair of glasses-streams video to a belt-worn computer, which converts the video into stimulus commands for the implant," says Weiland. "The belt-worn computer encodes the commands into a wireless signal that is transmitted to the implant, which has the necessary electronics to receive and decode both wireless power and data. Based on those data, the implant stimulates the retina with small electrical pulses. The electronics are hermetically packaged and the electrical stimulus is delivered to the retina via a microelectrode array." In 1998, Robert Greenberg founded Second Sight to develop the technology for the marketplace. While under development, the Argus I and Argus II systems have won wide recognition, including a 2010 Popular Mechanics Breakthrough Award and a 2009 R&D 100 Award, but it is only with FDA approval that the technology can now be made available to patients. "An artificial retina can offer hope to those with retinitis pigmentosa, as it may help them achieve a level of visual perception that enhances their quality of life, enabling them to perform functions of daily living more easily and the chance to enjoy simple pleasures we may take for granted," says Narayanan. "Such success is the result of fundamental studies in several fields, technology improvements based on those results and feedback from clinical trials--all enabled by sustained public and private investment from entities like NSF."  Contacts and sources: National Science Foundation, Source: Nano Patents And Innovation
Read More........